Blaise Coleman, Endo International CEO
July 1, 2022 09:06 AM EDTUpdated 11:14 AM
R&D

En­do adds to a pile­up of bad news as lead drug flunks PhII study

John Carroll

Editor & Founder

En­do In­ter­na­tion­al is adding some clin­i­cal woes to­day on top of its tox­ic pile­up of opi­oid lit­i­ga­tions.

The Dublin-based phar­ma put out word Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times